A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Chicago
BeOne Medicines
Mayo Clinic
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Acerta Pharma BV
H. Lee Moffitt Cancer Center and Research Institute
University of California, San Diego
Acerta Pharma BV
H. Lee Moffitt Cancer Center and Research Institute
Hoffmann-La Roche
Thomas Jefferson University
University of California, San Diego
M.D. Anderson Cancer Center
Center for International Blood and Marrow Transplant Research
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
American Regent, Inc.
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Johnson & Johnson Private Limited
Thomas Jefferson University
Mayo Clinic
BeiGene
Fred Hutchinson Cancer Center
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Pharmacyclics LLC.
AstraZeneca
Dana-Farber Cancer Institute
BeiGene
University of Rochester
M.D. Anderson Cancer Center
Pharmacyclics LLC.
University of Rochester
OrphAI Therapeutics
University of California, San Diego
Rhizen Pharmaceuticals SA
AbbVie
City of Hope Medical Center
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Rochester
Mayo Clinic
Barbara Ann Karmanos Cancer Institute
National Institutes of Health Clinical Center (CC)
University of Nebraska